منابع مشابه
Systemic therapy for colorectal cancer.
N Engl J Med 2005;352:476-87. Copyright © 2005 Massachusetts Medical Society. olorectal cancer is the third most common malignant disease and the second most frequent cause of cancer-related death in the United States, with 145,290 new cases and 56,290 deaths anticipated in 2005. 1 Worldwide, colorectal cancer is the fourth most commonly diagnosed malignant disease, with an estimated 1,023,000 ...
متن کاملSYSTEMIC THERAPY FOR COLORECTAL CANCER – OVERVIEW OF RECENT TRIAlS
Colorectal cancer (CRC) is the most common malignancy of the gastrointestinal tract worldwide, and also one of the leading causes of cancer-related mortality, accounting for more than 600000 deaths every year. Depending on the stage of the disease some patients who were surgically treated for CRC with curative intent require adjuvant chemotherapy (fluorouracile-based), which reduces the risk of...
متن کاملSingapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer
Introduction: The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore. Materials and Methods: The workgroup utilised a modifi ed ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. Results: Five i...
متن کاملSingapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
INTRODUCTION The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore. MATERIALS AND METHODS The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. RESULTS Five i...
متن کاملTherapy for metastatic colorectal cancer.
Median overall survival of metastatic colorectal cancer patients treated with first- and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arhiv za onkologiju
سال: 2003
ISSN: 0354-7310,1450-9520
DOI: 10.2298/aoo0304255s